Swiss firm Mymetics said on Wednesday it will start in 2008 Phase 1 trials of a possible anti-AIDS vaccine that seeks to produce mucosal antibodies that can resist HIV.
Swiss firm Mymetics said on Wednesday it will start in 2008 Phase 1 trials of a possible anti-AIDS vaccine that seeks to produce mucosal antibodies that can resist HIV.
The trials will take place in Belgium on a sample of between 30 to 40 women, Mymetics' scientific director Sylvain Fleury told journalists.
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure, no vaccine, and it is not under control." - National Commission on AIDS, 1993.
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure, no vaccine, and it is not under control." - National Commission on AIDS, 1993.
Any HIV vaccine that could successfully achieve antibody production into both genital and intestinal tracts might open the door to a new HIV vaccine approach, Mymetics claimed on its website.
The Swiss-based company, which is quoted on the Nasdaq stock index in New York, said it hopes to take its research further, and then either enter into a partnership with a larger company, or sell the product technology, in order to move to Phase III trials targeted at between 15,000-20,000 people.
The cost of such trials is too much for Mymetics to afford on its own, company chairman Christian Rochet said.
Mymetics estimates the vaccine could produce annual sales revenue of between two to four billion dollars (1.3-2.7 billion euros) per year.
Advertisement
LIN/M
